"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 1 | 4 |
| 2000 | 5 | 0 | 5 |
| 2001 | 8 | 2 | 10 |
| 2002 | 2 | 2 | 4 |
| 2003 | 11 | 5 | 16 |
| 2004 | 7 | 2 | 9 |
| 2005 | 10 | 7 | 17 |
| 2006 | 6 | 7 | 13 |
| 2007 | 13 | 1 | 14 |
| 2008 | 9 | 7 | 16 |
| 2009 | 10 | 5 | 15 |
| 2010 | 5 | 5 | 10 |
| 2011 | 8 | 5 | 13 |
| 2012 | 6 | 9 | 15 |
| 2013 | 9 | 11 | 20 |
| 2014 | 7 | 19 | 26 |
| 2015 | 9 | 28 | 37 |
| 2016 | 7 | 24 | 31 |
| 2017 | 9 | 24 | 33 |
| 2018 | 3 | 44 | 47 |
| 2019 | 12 | 34 | 46 |
| 2020 | 15 | 13 | 28 |
| 2021 | 18 | 15 | 33 |
| 2022 | 2 | 16 | 18 |
| 2023 | 3 | 6 | 9 |
| 2024 | 10 | 3 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024; 20(37):2915-2925.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
-
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024 Sep 05; 187(18):4905-4925.e24.
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
-
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 03; 46(3):228-238.
-
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 02 27; 8(4):842-845.
-
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). J Immunother Cancer. 2024 Feb 05; 12(2).
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.